Mortality after uveal and conjunctival melanoma: which tumour is more deadly?
- PMID: 18937804
- DOI: 10.1111/j.1755-3768.2008.01369.x
Mortality after uveal and conjunctival melanoma: which tumour is more deadly?
Abstract
Purpose: We aimed to model and compare mortality rates for uveal melanoma (UM) and conjunctival melanoma (CM) by adjusting for differences in tumour size and local recurrence.
Methods: Population-based mortality data for 240 and 85 patients with primary UM and CM and 91 and 23 patients with disseminated UM and CM, respectively, were compared with cumulative incidence analysis. Cox proportional hazards multivariate regression with time-dependent variables was used to adjust for differences in tumour diameter, thickness and recurrence rates.
Results: The 10-year cumulative incidences of metastatic death from UM and CM were 39% (95% confidence interval [CI] 33-45) and 32% (95% CI 21-44), respectively. After adjusting for tumour size, risk of death from CM was higher than from UM (hazard ratio [HR] 1.9; p = 0.039). Additional adjustment for more frequent local recurrence of CM diminished the difference (HR 1.5; p = 0.25). Survival periods after systemic metastasis of UM and CM were comparable (median 8 months).
Conclusions: Clinical observations show longer survival after primary CM than after primary UM. This reflects the smaller average size of CM. However, a primary CM of a given size is more deadly than a UM of equivalent size because primary CM tends to recur after treatment and, possibly, because additional lymphatic dissemination occurs with CM.
Comment in
-
Who's the faster runner: the cheetah or the rabbit?Acta Ophthalmol. 2009 Mar;87(2):148. doi: 10.1111/j.1755-3768.2008.01334.x. Acta Ophthalmol. 2009. PMID: 19292856 No abstract available.
Similar articles
-
Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients.Trans Am Ophthalmol Soc. 2000;98:471-92. Trans Am Ophthalmol Soc. 2000. PMID: 11190037 Free PMC article.
-
A prognostic model and staging for metastatic uveal melanoma.Cancer. 2003 Jan 15;97(2):465-75. doi: 10.1002/cncr.11113. Cancer. 2003. PMID: 12518371
-
Conjunctival melanoma in the Netherlands: a nationwide study.Invest Ophthalmol Vis Sci. 2005 Jan;46(1):75-82. doi: 10.1167/iovs.04-0344. Invest Ophthalmol Vis Sci. 2005. PMID: 15623757
-
[Malignant conjunctival melanoma. Clinical review with recommendations for diagnosis, therapy and follow-up].Klin Monbl Augenheilkd. 2002 Oct;219(10):710-21. doi: 10.1055/s-2002-35693. Klin Monbl Augenheilkd. 2002. PMID: 12447715 Review. German.
-
Screening for conjunctival melanoma metastasis: literature review.Bull Soc Belge Ophtalmol. 2007;(306):23-30. Bull Soc Belge Ophtalmol. 2007. PMID: 18251451 Review.
Cited by
-
Genomic and transcriptomic landscape of conjunctival melanoma.PLoS Genet. 2020 Dec 31;16(12):e1009201. doi: 10.1371/journal.pgen.1009201. eCollection 2020 Dec. PLoS Genet. 2020. PMID: 33383577 Free PMC article.
-
Therapeutic efficacy by targeting correction of Notch1-induced aberrants in uveal tumors.PLoS One. 2012;7(8):e44301. doi: 10.1371/journal.pone.0044301. Epub 2012 Aug 28. PLoS One. 2012. PMID: 22937170 Free PMC article.
-
Advances in the management of conjunctival melanoma.Surv Ophthalmol. 2017 Jan-Feb;62(1):26-42. doi: 10.1016/j.survophthal.2016.06.001. Epub 2016 Jun 16. Surv Ophthalmol. 2017. PMID: 27321895 Free PMC article. Review.
-
A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib.BMC Cancer. 2016 Aug 12;16:634. doi: 10.1186/s12885-016-2657-7. BMC Cancer. 2016. PMID: 27520988 Free PMC article.
-
The SDF-1/CXCR4 chemokine axis in uveal melanoma cell proliferation and migration.Tumour Biol. 2016 Mar;37(3):4175-82. doi: 10.1007/s13277-015-4259-4. Epub 2015 Oct 22. Tumour Biol. 2016. PMID: 26490988
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
